SCHEMBL22836089

SCHEMBL22836089

Cc1ccc(S(=O)(=O)O)c(C2CCC(CO)CC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.37
ESR2 Q92731 6/20 0.37
CYP2C9 P11712 3/20 0.37
CYP3A4 P08684 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
AKR1C3 P42330 1/20 0.36
CYP2D6 P10635 1/20 0.34
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
EPHX2 P34913 3/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
TRPM5 Q9NZQ8 1/20 0.32
KDM4C Q9H3R0 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
MEP1B Q16820 1/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9101971 0.89 PTGDR2 (0.39) PTGDR2CYP2D6DRD2DRD4DRD3
SCHEMBL2217850 0.85 PTGDR2 (0.46) PTGDR2EPHX2MEN1ALDH1A1KMT2A
SCHEMBL23702398 0.84 PTGDR2 (0.36) ESR1ESR2CYP2C9CYP3A4PTGDR2
SCHEMBL3387056 0.84 PTGDR2 (0.36) ESR2PTGDR2DRD2DRD4DRD3
SCHEMBL30764027 0.83 PTGDR2 (0.43) PTGDR2EPHX2L3MBTL1TSHR
SCHEMBL5278348 0.83 PTGDR2 (0.47) PTGDR2EPHX2MEN1ALDH1A1KMT2A
SCHEMBL778056 0.82 PTGDR2 (0.35) PTGDR2DRD2DRD4DRD3EPHX2
SCHEMBL28966936 0.82 HTR6 (0.44) CYP2D6MEN1ALDH1A1KMT2A
SCHEMBL361128 0.82 PTGDR2 (0.49) CYP3A4PTGDR2EPHX2MEN1ALDH1A1
SCHEMBL9099567 0.81 SCN9A (0.38) CYP3A4PTGDR2EPHX2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 US disclosed
US-20230416242-A1 DOUBLE DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-28 US disclosed
CN-114502158-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2022-05-13 CN disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416242-A1 DOUBLE DEGRADERS AND USES THEREOF DCXR, IDUA, GUSB ESR1 1164/4885ESR2 1804/4885CYP2C9 146/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ESR1 791/4885ESR2 2271/4885CYP2C9 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.